The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2019 | CLL: IgHV mutational status
Nicolas Martinez-Calle, MD, Nottingham University Hospitals NHS Trust, Nottingham, UK, outlines what he believes to be the most influential findings in chronic lymphocytic leukemia (CLL) research, specifically mentioning the use of IgHV mutational status in the personalization of CLL therapy This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.
